Guidelines for the safe administration of high-dose interleukin-2

J Immunother. Jul-Aug 2001;24(4):287-93. doi: 10.1097/00002371-200107000-00004.

Abstract

High-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8% of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients with metastatic melanoma and renal cell carcinoma. Interleukin-2 administration is associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. This article details practical guidelines for the safe administration of high-dose IL-2.

Publication types

  • Review

MeSH terms

  • Capillary Leak Syndrome / chemically induced
  • Capillary Leak Syndrome / diagnosis
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Drug Administration Schedule
  • Fluid Therapy
  • Humans
  • Hypotension / etiology
  • Hypotension / therapy
  • Interleukin-2 / administration & dosage*
  • Interleukin-2 / adverse effects
  • Interleukin-2 / therapeutic use
  • Melanoma / drug therapy*
  • Melanoma / secondary
  • Pleural Effusion / chemically induced
  • Pleural Effusion / therapy

Substances

  • Interleukin-2